in

TODD EVERHART, MD
Clinical Vice President
Internal Medicine

Dr. Everhart is an innovator, educator, and leader in the pharmaceutical and biotechnology industries with over 25 years of experience in the practice of medicine and over 14 years of experience in clinical research.  Board-certified in Internal Medicine and a Fellow of the American College of Physicians, he is one of Signant Health’s experts in decentralized trials, rater training, blinded data analytics, and placebo response mitigation. 

in

BILL BYROM, PhD
Vice President, Product Intelligence & Positioning

Dr. Byrom has worked in the pharmaceutical industry for 30 years. He has authored over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO). His recent scientific work includes the use of wearable technology and bring-your-own-device (BYOD) eCOA in clinical trials

in

LEW FREDANE, MD
Clinical Vice President
Neurology

Dr. Fredane serves as the Therapeutic Area Leader for neurology, overseeing Signant’s eCOA, rater training, and quality assurance work. He has experience as a practicing neurologist, clinical assistant professor, and in the drug development for over 15 years.

JOAN BUSNER, PhD
Clinical Vice President
Pediatrics, Orphan Diseases, 
Mood & Anxiety

Dr. Busner has over 35 years of experience as an academic psychiatric researcher and psychopharmacology principal investigator, and founded and directed two university psychiatric clinical trials units. Dr. Busner served continuously on University Institutional Review Boards for 20 years. At Signant she has scientific and clinical responsibility for studies in mood, anxiety, pediatrics, and rare/orphan diseases. She has overseen hundreds of trials and trained thousands of raters. Dr. Busner is currently Affiliate Associate Professor of Psychiatry at Virginia Commonwealth University.

in

GARY SACHS, MD
Clinical Vice President
Mood Disorders

Dr. Sachs is the Therapeutic Area Leader in bipolar disease and mood disorders at Signant. He lends his extensive experience in rater training and the methodologies of mood and anxiety disorder research to support studies. 

LET'S MEET
in

DAVID DANIEL, MD
Executive Advisor, Schizophrenia

Dr. Daniel has over 25 years of experience overseeing rater training and data quality management programs in various settings. He has supervised countless clinical trials for schizophrenia and bipolar disorder. In addition to his work with Signant, David serves as Clinical Professor of Psychiatry at George Washington University. 

Dr. Kott is based in Signant’s Prague office and until recently was Senior Clinical Manager for Europe. Having led the development of the Data Analytics Program for Bracket, he has overseen the design and reporting of data analytics in multiple large schizophrenia studies. For the past seven years, he has also provided training to investigators as an Expert Trainer.

ALAN KOTT, MUDr
Clinical Vice President & Practice Lead, Data Analytics

in

MEET THE SIGNANT EXPERTS

Study design  |  Outcome measure selection  |  eCOA modality choice  |  Telemedicine clinician assessments
eCOA design  |  PRO dossier support  |  Rater training  |  Data quality monitoring & analytics
Wearables & sensors  |  Selection and implementation  |  
Innovative technology and novel endpoints

At Signant Health, we combine our technology with robust clinical, scientific, and regulatory expertise to guide your study from design to regulatory submission, ensuring the generation of clinical evidence of the highest quality and integrity.

We help you reach your study goals.

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at  www.signanthealth.com.  


STEPHAN BART, SR MD CPI
Executive Advisor
Infectious Disease, Vaccines, Science & Medicine

Dr. Bart is both Board certified and a Certified Physician Investigator with a broad therapeutic scope including successful completion of more than 450 domestic and international phase 1 through 3 human clinical trials. He has maintained a successful private practice, held faculty positions at Penn State University and the University of Maryland Medical Center, as well as published many articles in prestigious peer reviewed journals. Dr. Bart is an industry key opinion leader in several areas, with extensive focus on advancing vaccine and immunology research over the past decade. 

in

DAVID MILLER, MD MA
Clinical Vice President

Dementia, Geriatrics

Dr. Miller is a geriatric psychiatrist by training. He has over 25 years of experience in patient care, clinical research, teaching, and even served as a principal investigator for dementia studies. David currently serves as the Chair of the Alzheimer’s Association Research Roundtable.

STEVEN TARGUM, MD
Scientific Director, 
Schizophrenia & Mood Disorders

Dr. Targum consults widely to the pharmaceutical industry regarding the design and implementation of clinical trials for new psychotropic drugs and the progression of drug development from concept to approval to launch. 
In addition to his work at Signant, Dr. Targum is a Chief Medical Advisor at Prana Biotechnology Ltd. and has served as Chief Medical Officer at several small biotechnology and pharmaceutical companies.

in

MANUELA BOSSI, PhD
Scientific Advisor

Dr. Bossi has authored numerous articles on vision neuroscience, focusing on human binocular vision and perception. From questionnaire creation and administration to data best practices and consent, Manuela’s clinical research experience within academic and NHS institutions will guide researchers through trial challenges.

in

DAWIE WESSELS, MD
Chief Medical Officer

Dr. Daniel has over 25 years of experience overseeing rater training and data quality management programs in various settings. He has supervised countless clinical trials for schizophrenia and bipolar disorder. In addition to his work with Signant, David serves as Clinical Professor of Psychiatry at George Washington University. 

As Chief Medical Officer of Signant Health, Dawie’s deep expertise across multiple therapeutic areas, multinational development leadership, and experience in associated commercial growth supports the expanding impact of the Signant Science and Medical team. With over twenty years' experience combining medicine and business, Dawie oversees Signant's scientific and operational strategies. 

With more than 50 full-time, in-house experts, we are prepared to advise on all areas of eCOA science and best practice including:

We help you reach your study goals.

LET'S MEET
in

GRETA MARIE DE WAAL, PhD
Clinical Scientist, Digital Health & eCOA Science

Dr. de Waal provides scientific consultation to clients relating to the implementation of electronic clinical outcome assessments. Dr. de Waal has 2+ years’ experience in the clinical research industry, previously forming part of a Medical Strategy team. She has been supporting projects across a wide variety of therapeutic areas, including oncology, infectious disease, and dermatology. 

in

BRANDEN KUSANTO, PhD
Clinical Scientist, eCOA Science

Dr. Kusanto studied bioengineering at Oregon State University before completing his PhD in platelet biology at Hull York Medical School. At Signant, he specializes in eCOA, eConsent, and multiple therapeutic areas like, dermatology, gastroenterology, pediatrics, and rare diseases.